Biotricity Provides Updated Guidance for Earlier Than Expected Path to Profitability Due to Growing Revenues and Improving Margins
Biotricity Provides Updated Guidance for Earlier Than Expected Path to Profitability Due to Growing Revenues and Improving Margins
The company has achieved EBIDTA positive on a go-forward cash basis
按未來現金計算,該公司已實現息稅折舊攤銷前利潤爲正
REDWOOD CITY, CA / ACCESSWIRE / October 3, 2024 / Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company that is reshaping the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today reports compelling financial and strategic advancements that will propel the company towards profitability by the end of Fiscal Q4. Biotricity is now on an accelerated trajectory to profitability due to growing revenues from sales and strategic partnerships, improving margins, and an earlier than expected milestone of achieving EBITDA positive on a go-forward cash basis.
加利福尼亞州雷德伍德城/ACCESSWIRE/2024年10月3日/Biotricity Inc.(OTCQB: BTCY)是一家創新的技術即服務(TaaS)公司,正在通過最先進的遠程監控和診斷解決方案重塑醫療行業的格局。該公司今天報告了引人注目的財務和戰略進展,這將推動該公司在第四財年末實現盈利。由於銷售和戰略合作伙伴關係收入的增長,利潤率的提高,以及按未來現金計算實現息稅折舊攤銷前利潤爲正的里程碑早於預期,Biotricity現在正加速實現盈利。
Biotricity is committed to leveraging its cutting-edge technology suite to meet the evolving needs of the healthcare sector, bridging the wide gap in care delivery for both medical providers and patients. The company's strategic initiatives and solid financial foundation position it to capitalize on market opportunities and continue to drive sustainable growth. For more information about Biotricity Inc. and its revolutionary suite of healthcare solutions, please visit .
Biotricity致力於利用其尖端技術套件來滿足醫療保健行業不斷變化的需求,彌合醫療提供者和患者在護理服務方面的巨大差距。該公司的戰略舉措和堅實的財務基礎使其能夠利用市場機會並繼續推動可持續增長。有關Biotricity Inc.及其革命性醫療解決方案套件的更多信息,請訪問。
About Biotricity Inc.
關於 Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit .
Biotricity正在通過彌合遠程監測和慢性護理管理方面的差距來改革醫療保健市場。醫生和患者信任 Biotricity 無與倫比的預防和個人護理標準,包括慢性病的診斷和診斷後解決方案。該公司爲醫療和消費市場開發全面的遠程健康監測解決方案。要了解更多信息,請訪問。
Important Cautions Regarding Forward-Looking Statements
關於前瞻性陳述的重要注意事項
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
本新聞稿中包含的任何未描述歷史事實的陳述都可能構成前瞻性陳述。前瞻性陳述涉及假設並描述了我們未來的計劃、戰略和預期,通常可以通過使用 「可能」、「應該」、「將」、「將」、「可以」、「計劃」、「期望」、「預期」、「估計」、「相信」、「打算」、「尋求」、「項目」 或 「目標」 等詞或這些詞的否定詞或這些詞語的其他變體來識別術語。前瞻性陳述可能包括但不限於關於 (i) 管理層未來運營的計劃、目標和目標的陳述,包括與Bioflux或公司任何其他擬議產品或服務的設計、開發和商業化有關的計劃、目標或目標,(ii) 收入(包括收益/虧損)、每股收益(包括收益/虧損)、資本支出、股息、資本結構或其他財務項目的預測,(iii) 公司未來的財務業績,(iv)監管公司運營或打算運營的制度以及 (v) 上述第 (i)、(ii)、(iii) 或 (iv) 點所述任何陳述所依據或與之相關的假設。此類前瞻性陳述並不旨在預測或保證實際業績、業績、事件或情況,可能無法實現,因爲它們基於公司當前的預測、計劃、目標、信念、預期、估計和假設,並受許多風險和不確定性以及其他影響的影響,其中許多是公司無法控制的。由於這些風險和不確定性,某些事件和情況的實際結果和時間可能與前瞻性陳述所描述的結果存在重大差異。可能影響或助長前瞻性陳述不準確或導致實際業績與預期或預期業績存在重大差異的因素可能包括但不限於公司無法獲得額外融資、與產品開發相關的時間和資源過長以及相關的現金流不足以及由此產生的流動性不足、公司無法擴大公司業務、政府對醫療器械和醫療保健行業的嚴格監管、缺乏產品多元化、現有競爭或競爭加劇、仲裁和訴訟結果、股票波動和流動性不足,以及公司未能實施公司的業務計劃或戰略。公司向美國證券交易委員會提交的文件中對這些因素和其他因素進行了更詳細的識別和描述。無法保證公司一定會盈利。公司沒有義務更新任何前瞻性陳述以反映本新聞稿發佈之日之後可能出現的任何事件或情況。
Investor relations:
投資者關係:
Biotricity Investor Relations
Investors@biotricity.com
Biotricity 投資者關係
Investors@biotricity.com
SOURCE: Biotricity, Inc.
來源:Biotricity, Inc.